Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

EFOMP policy statement NO. 19 : Dosimetry in nuclear medicine therapy – Molecular radiotherapy

Sjögreen-Gleisner, Katarina LU ; Flux, Glenn ; Bacher, Klaus ; Chiesa, Carlo ; de Nijs, Robin ; Kagadis, George C. ; Lima, Thiago ; Georgosopoulou, Maria Lyra ; Gabiña, Pablo Minguez and Nekolla, Stephan , et al. (2023) In Physica Medica
Abstract

The European Council Directive 2013/59/Euratom (BSS Directive) includes optimisation of treatment with radiotherapeutic procedures based on patient dosimetry and verification of the absorbed doses delivered. The present policy statement summarises aspects of three directives relating to the therapeutic use of radiopharmaceuticals and medical devices, and outlines the steps needed for implementation of patient dosimetry for radioactive drugs. To support the transition from administrations of fixed activities to personalised treatments based on patient-specific dosimetry, EFOMP presents a number of recommendations including: increased networking between centres and disciplines to support data collection and development of... (More)

The European Council Directive 2013/59/Euratom (BSS Directive) includes optimisation of treatment with radiotherapeutic procedures based on patient dosimetry and verification of the absorbed doses delivered. The present policy statement summarises aspects of three directives relating to the therapeutic use of radiopharmaceuticals and medical devices, and outlines the steps needed for implementation of patient dosimetry for radioactive drugs. To support the transition from administrations of fixed activities to personalised treatments based on patient-specific dosimetry, EFOMP presents a number of recommendations including: increased networking between centres and disciplines to support data collection and development of codes-of-practice; resourcing to support an infrastructure that permits routine patient dosimetry; research funding to support investigation into individualised treatments; inter-disciplinary training and education programmes; and support for investigator led clinical trials. Close collaborations between the medical physicist and responsible practitioner are encouraged to develop a similar pathway as is routine for external beam radiotherapy and brachytherapy. EFOMP's policy is to promote the roles and responsibilities of medical physics throughout Europe in the development of molecular radiotherapy to ensure patient benefit. As the BSS directive is adopted throughout Europe, unprecedented opportunities arise to develop informed treatments that will mitigate the risks of under- or over-treatments.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
in press
subject
in
Physica Medica
article number
103166
publisher
ISTITUTI EDITORIALI E POLGRAFICI INTERNAZIONALI
external identifiers
  • pmid:37926641
  • scopus:85176287118
ISSN
1120-1797
DOI
10.1016/j.ejmp.2023.103166
language
English
LU publication?
yes
id
87beb5c3-6d00-4053-ae53-186ff55a09a0
date added to LUP
2024-01-11 11:14:30
date last changed
2024-04-12 04:06:44
@article{87beb5c3-6d00-4053-ae53-186ff55a09a0,
  abstract     = {{<p>The European Council Directive 2013/59/Euratom (BSS Directive) includes optimisation of treatment with radiotherapeutic procedures based on patient dosimetry and verification of the absorbed doses delivered. The present policy statement summarises aspects of three directives relating to the therapeutic use of radiopharmaceuticals and medical devices, and outlines the steps needed for implementation of patient dosimetry for radioactive drugs. To support the transition from administrations of fixed activities to personalised treatments based on patient-specific dosimetry, EFOMP presents a number of recommendations including: increased networking between centres and disciplines to support data collection and development of codes-of-practice; resourcing to support an infrastructure that permits routine patient dosimetry; research funding to support investigation into individualised treatments; inter-disciplinary training and education programmes; and support for investigator led clinical trials. Close collaborations between the medical physicist and responsible practitioner are encouraged to develop a similar pathway as is routine for external beam radiotherapy and brachytherapy. EFOMP's policy is to promote the roles and responsibilities of medical physics throughout Europe in the development of molecular radiotherapy to ensure patient benefit. As the BSS directive is adopted throughout Europe, unprecedented opportunities arise to develop informed treatments that will mitigate the risks of under- or over-treatments.</p>}},
  author       = {{Sjögreen-Gleisner, Katarina and Flux, Glenn and Bacher, Klaus and Chiesa, Carlo and de Nijs, Robin and Kagadis, George C. and Lima, Thiago and Georgosopoulou, Maria Lyra and Gabiña, Pablo Minguez and Nekolla, Stephan and Peters, Steffie and Santos, Joao and Sattler, Bernhard and Stokke, Caroline and Tran-Gia, Johannes and Gilligan, Paddy and Bardiès, Manuel}},
  issn         = {{1120-1797}},
  language     = {{eng}},
  publisher    = {{ISTITUTI EDITORIALI E POLGRAFICI INTERNAZIONALI}},
  series       = {{Physica Medica}},
  title        = {{EFOMP policy statement NO. 19 : Dosimetry in nuclear medicine therapy – Molecular radiotherapy}},
  url          = {{http://dx.doi.org/10.1016/j.ejmp.2023.103166}},
  doi          = {{10.1016/j.ejmp.2023.103166}},
  year         = {{2023}},
}